Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Navigation/Suche

• Forscher*innen.
• Institutionen.
• Projekte.
• Publikationen.
• Partner.
• Geldgeber.
• Ausstattung.
• Knowhow.
• Forschungsfelder.

Publikationen

Suchbegriffe: SGLT2, . Treffer: 17

2022

Kolesnik, E; Scherr, D; Rohrer, U; Benedikt, M; Manninger, M; Sourij, H; von, Lewinski, D SGLT2 Inhibitors and Their Antiarrhythmic Properties.
Int J Mol Sci. 2022; 23(3): Doi: 10.3390/ijms23031678 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

von, Lewinski, D; Tripolt, NJ; Sourij, H; Pferschy, PN; Oulhaj, A; Alber, H; Gwechenberger, M; Martinek, M; Seidl, S; Moertl, D; Nürnberg, M; Roithinger, FX; Steinwender, C; Stühlinger, M; Zirlik, A; Benedikt, M; Kolesnik, E; Wallner, M; Rohrer, U; Manninger, M; Scherr, D, , ERASe, study, group Ertugliflozin to reduce arrhythmic burden in ICD/CRT patients (ERASe-trial) - A phase III study.
Am Heart J. 2022; 246:152-160 Doi: 10.1016/j.ahj.2022.01.008
Web of Science PubMed FullText FullText_MUG

 

Wicik, Z; Nowak, A; Jarosz-Popek, J; Wolska, M; Eyileten, C; Siller-Matula, JM; von, Lewinski, D; Sourij, H; Filipiak, KJ; Postuła, M Characterization of the SGLT2 Interaction Network and Its Regulation by SGLT2 Inhibitors: A Bioinformatic Analysis.
Front Pharmacol. 2022; 13: 901340 Doi: 10.3389/fphar.2022.901340 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Zügner, E; Yang, HC; Kotzbeck, P; Boulgaropoulos, B; Sourij, H; Hagvall, S; Elmore, CS; Esterline, R; Moosmang, S; Oscarsson, J; Pieber, TR; Peng, XR; Magnes, C Differential In Vitro Effects of SGLT2 Inhibitors on Mitochondrial Oxidative Phosphorylation, Glucose Uptake and Cell Metabolism.
Int J Mol Sci. 2022; 23(14): Doi: 10.3390/ijms23147966 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

2021

Abdellatif, M; Lam, CSP Scientists on the Spot: A fraction of wisdom on heart failure
CARDIOVASC RES. 2021; 117(9): E114-E115. Doi: 10.1093/cvr/cvab230
Web of Science PubMed FullText FullText_MUG

 

Gager, GM; Gelbenegger, G; Jilma, B; von, Lewinski, D; Sourij, H; Eyileten, C; Filipiak, K; Postula, M; Siller-Matula, JM Cardiovascular Outcome in Patients Treated With SGLT2 Inhibitors for Heart Failure: A Meta-Analysis.
Front Cardiovasc Med. 2021; 8: 691907 Doi: 10.3389/fcvm.2021.691907 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Gager, GM; von, Lewinski, D; Sourij, H; Jilma, B; Eyileten, C; Filipiak, K; Hülsmann, M; Kubica, J; Postula, M; Siller-Matula, JM Effects of SGLT2 Inhibitors on Ion Homeostasis and Oxidative Stress associated Mechanisms in Heart Failure.
Biomed Pharmacother. 2021; 143:112169 Doi: 10.1016/j.biopha.2021.112169 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Hecking, M; Sharif, A; Eller, K; Jenssen, T Management of post-transplant diabetes: immunosuppression, early prevention, and novel antidiabetics.
Transpl Int. 2021; 34(1):27-48 Doi: 10.1111/tri.13783 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Katzmann, JL; Mason, AM; März, W; Kleber, ME; Niessner, A; Blüher, M; Speer, T; Laufs, U Genetic Variation in Sodium-glucose Cotransporter 2 and Heart Failure.
CLIN PHARMACOL THER. 2021; 11(2): Doi: 10.1002/cpt.2153 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Rau, M; Thiele, K; Korbinian, Hartmann, NU; Möllmann, J; Wied, S; Böhm, M; Scharnagl, H; März, W; Marx, N; Lehrke, M Effects of empagliflozin on lipoprotein subfractions in patients with type 2 diabetes: data from a randomized, placebo-controlled study.
Atherosclerosis. 2021; 330: 8-13. Doi: 10.1016/j.atherosclerosis.2021.06.915
Web of Science PubMed FullText FullText_MUG

 

von, Lewinski, D; Benedikt, M; Tripolt, N; Wallner, M; Sourij, H; Kolesnik, E Can sodium-glucose cotransporter 2 inhibitors be beneficial in patients with acute myocardial infarction?
Kardiol Pol. 2021; 79(5):503-509 Doi: 10.33963/KP.15969 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

2020

Koyani, CN; Plastira, I; Sourij, H; Hallström, S; Schmidt, A; Rainer, PP; Bugger, H; Frank, S; Malle, E; von, Lewinski, D Empagliflozin protects heart from inflammation and energy depletion via AMPK activation.
Pharmacol Res. 2020; 158:104870 Doi: 10.1016/j.phrs.2020.104870
Web of Science PubMed FullText FullText_MUG

 

Tripolt, NJ; Kolesnik, E; Pferschy, PN; Verheyen, N; Ablasser, K; Sailer, S; Alber, H; Berger, R; Kaulfersch, C; Leitner, K; Lichtenauer, M; Mader, A; Moertl, D; Oulhaj, A; Reiter, C; Rieder, T; Saely, CH; Siller-Matula, J; Weidinger, F; Zechner, PM; von Lewinski, D; Sourij, H; EMMY study group Impact of EMpagliflozin on cardiac function and biomarkers of heart failure in patients with acute MYocardial infarction-The EMMY trial.
Am Heart J. 2020; 221:39-47 Doi: 10.1016/j.ahj.2019.12.004 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

2019

Schernthaner, G; Drexel, H; Moshkovich, E; Zilaitiene, B; Martinka, E; Czupryniak, L; Várkonyi, T; Janež, A; Ducena, K; Lalić, K; Tankova, T; Prázný, M; Smirčić Duvnjak, L; Sukhareva, O; Sourij, H SGLT2 inhibitors in T2D and associated comorbidities - differentiating within the class.
BMC ENDOCR DISORD. 2019; 19(1): 64-64. Doi: 10.1186/s12902-019-0387-y [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

2016

Ferrannini, E; Baldi, S; Frascerra, S; Astiarraga, B; Heise, T; Bizzotto, R; Mari, A; Pieber, TR; Muscelli, E Shift to Fatty Substrate Utilization in Response to Sodium-Glucose Cotransporter 2 Inhibition in Subjects Without Diabetes and Patients With Type 2 Diabetes.
Diabetes. 2016; 65(5):1190-1195 Doi: 10.2337/db15-1356 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

2015

Pieber, TR; Famulla, S; Eilbracht, J; Cescutti, J; Soleymanlou, N; Johansen, OE; Woerle, HJ; Broedl, UC; Kaspers, S Empagliflozin as adjunct to insulin in patients with type 1 diabetes: a 4-week, randomized, placebo-controlled trial (EASE-1).
Diabetes Obes Metab. 2015; 17(10):928-935 Doi: 10.1111/dom.12494 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

2010

von Lewinski, D; Rainer, PP; Gasser, R; Huber, MS; Khafaga, M; Wilhelm, B; Haas, T; Mächler, H; Rössl, U; Pieske, B Glucose-transporter-mediated positive inotropic effects in human myocardium of diabetic and nondiabetic patients.
Metabolism. 2010; 59(7):1020-1028 Doi: 10.1016/j.metabol.2009.10.025
Web of Science PubMed FullText FullText_MUG

 

↑ Seitenanfang / Navigation

© Med Uni Graz • Impressum